Alaunos Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
TCRT
- Investments
-
3
- Share Price
-
$1.61
- (As of Friday Closing)
Alaunos Therapeutics General Information
Description
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Contact Information
Website
www.alaunos.comCorporate Office
- 501 East Las Olas Boulevard
- Suite 300
- Fort Lauderdale, FL 33301
- United States
Corporate Office
- 501 East Las Olas Boulevard
- Suite 300
- Fort Lauderdale, FL 33301
- United States
Alaunos Therapeutics Stock Performance
As of 13-Nov-2026, Alaunos Therapeutics’s stock price is $1.61. Its current market cap is $6.86M with 4.21M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.61 | $1.62 | $0.72 - $4.50 | $6.86M | 4.21M | 7.44M | -$1.76 |
Alaunos Therapeutics Financials Summary
As of 30-Jun-2026, Alaunos Therapeutics has a trailing 12-month revenue of $3K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,165 | 5,271 | 1,367 | 6,239 |
| Revenue | 3 | 5 | 10 | 5 |
| EBITDA | (3,986) | (4,169) | (4,677) | (30,904) |
| Net Income | (4,010) | (4,176) | (4,679) | (35,140) |
| Total Assets | 1,516 | 2,966 | 2,755 | 8,263 |
| Total Debt | 0 |
Alaunos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alaunos Therapeutics Comparisons
Industry
Financing
Details
Alaunos Therapeutics Competitors (42)
One of Alaunos Therapeutics’s 42 competitors is Nexoplex bio, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nexoplex bio | Formerly VC-backed | Emeryville, CA | ||||
| Abivax | Formerly PE-Backed | Paris, France | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium |
Alaunos Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alaunos Therapeutics Patents
Alaunos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025122800-A1 | Identification of neoantigen-reactive t cell receptors | Inactive | 06-Dec-2023 | ||
| WO-2025122800-A9 | Identification of neoantigen-reactive t cell receptors | Inactive | 06-Dec-2023 | ||
| US-20260273054-A1 | Identification of neoantigen-reactive t cell receptors | Pending | 21-Mar-2023 | ||
| WO-2024197072-A2 | Identification of neoantigen-reactive t cell receptors | Inactive | 21-Mar-2023 | ||
| WO-2024197072-A3 | Identification of neoantigen-reactive t cell receptors | Inactive | 21-Mar-2023 | G01N33/505 |
Alaunos Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alaunos Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alaunos Therapeutics Investments & Acquisitions (3)
Alaunos Therapeutics’s most recent deal was a Reverse Merger with Velaris Therapeutics. The deal was made on 13-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Velaris Therapeutics | 13-Oct-2026 | Reverse Merger | Drug Discovery | ||
| Eden BioCell | 18-Dec-2018 | Joint Venture | Drug Delivery | ||
| EasyWeb | 13-Sep-2005 | Merger/Acquisition | Media and Information Services (B2B) |
Alaunos Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.84 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Alaunos Therapeutics FAQs
-
When was Alaunos Therapeutics founded?
Alaunos Therapeutics was founded in 1998.
-
Where is Alaunos Therapeutics headquartered?
Alaunos Therapeutics is headquartered in Fort Lauderdale, FL.
-
What is the size of Alaunos Therapeutics?
Alaunos Therapeutics has 34 total employees.
-
What industry is Alaunos Therapeutics in?
Alaunos Therapeutics’s primary industry is Drug Discovery.
-
Is Alaunos Therapeutics a private or public company?
Alaunos Therapeutics is a Public company.
-
What is Alaunos Therapeutics’s stock symbol?
The ticker symbol for Alaunos Therapeutics is TCRT.
-
What is the current stock price of Alaunos Therapeutics?
As of 13-Nov-2026 the stock price of Alaunos Therapeutics is $1.61.
-
What is the current market cap of Alaunos Therapeutics?
The current market capitalization of Alaunos Therapeutics is $6.86M.
-
What is Alaunos Therapeutics’s current revenue?
The trailing twelve month revenue for Alaunos Therapeutics is $3K.
-
Who are Alaunos Therapeutics’s competitors?
Nexoplex bio, Abivax, BioMarin Pharmaceutical, Inovio Pharmaceuticals, and Agomab Therapeutics are some of the 42 competitors of Alaunos Therapeutics.
-
What is Alaunos Therapeutics’s annual earnings per share (EPS)?
Alaunos Therapeutics’s EPS for 12 months was -$1.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
